We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
How to start niraparib in real-world Asian ovarian cancer patients?
- Authors
Sook-Hee Hong
- Abstract
The AGO-OVAR 16 pazopanib maintenance study suggested that the uneven distribution of the BRCA mutation group in Asian ovarian cancer patients may affect the different clinical outcomes of pazopanib therapy compared to that of Western patients [ 12]. 1/4 https://ejgo.org Poly (ADP-ribose) polymerases (PARPs) inhibitors are the current standard treatment for ovarian cancer along with platinum-based chemotherapy. However, in case of Asian patients there was no chance to participate in clinical trials of niraparib, and so it is necessary to evaluate whether this ISD is applicable to Asian ovarian cancer patients and whether niraparib's efficacy is consistent, especially in HRD-positive Asian ovarian cancer patients. Therefore, to apply niraparib maintenance therapy to all platinum-sensitive patients, it is also necessary to analyze the proportion of HRD-positive patients among Asian platinumsensitive ovarian cancer patients, considering the current limited availability of the Myriad HRD test.
- Subjects
CANCER patients; EAST Asians
- Publication
Journal of Gynecologic Oncology, 2021, Vol 32, Issue 2, p1
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2021.32.e36